Long-term follow-up study for PAH patients from TripleTRE
Part of Lungs & breathing clinical trials.
This study follows up with people who previously took part in another PAH study called TripleTRE. It observes their long-term treatment and health outcomes without giving any new medication. If you were in TripleTRE, you may be able to continue sharing your experiences.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been part of the TripleTRE study before.
- You have not been lost to follow-up (the study team still has your contact info).
- You are still taking at least one PAH medication (you haven't stopped all treatment, e.g., after a lung transplant).
- You did not leave the TripleTRE study because of not following its rules (like missing visits or not taking medicines).
- You are willing and able to sign a consent form to join this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study provides continued access to an investigational inhaled medicine (treprostinil palmitil inhalation powder) for people with pulmonary arterial hypertension (PAH) or pulmonary hypertension linked to interstitial lung disease (PH-ILD) who have already been in earlier studies of this treatment. It allows you to keep receiving the treatment under medical supervision.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This trial is for people with pulmonary arterial hypertension (PAH) who have already completed a previous study of the drug seralutinib. It offers continued access to the treatment so doctors can watch its safety and effects over a longer time.
This study tests whether regular remote check-ins and guidance can help people with pulmonary arterial hypertension stick to their treatment plan. You would be followed by phone or video from University of Sao Paulo.
This trial is a long-term follow-up study for people who already completed a previous study of an inhaled treprostinil medication (TPIP) for pulmonary hypertension caused by interstitial lung disease (PH-ILD). It tests whether continued treatment with TPIP is safe and effective over a longer period.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.